Cargando…

Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

BACKGROUND: CYP39A1 is a poorly characterized metabolic enzyme that has been investigated in a few tumors. However, the role of CYP39A1 in hepatocellular carcinoma (HCC) has not yet been clarified. In this study, the expression and clinical significance of CYP39A1 in HCC were explored. METHODS: CYP3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dan, Yu, Tao, Hu, Junjie, Wu, Jie, Feng, Shi, Xu, Qingxue, Zhu, Hua, Zhang, Xu, Zhang, Yonggang, Zhou, BenHong, Gu, Lijuan, Zeng, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741352/ https://www.ncbi.nlm.nih.gov/pubmed/35003516 http://dx.doi.org/10.1155/2021/5175581

Ejemplares similares

Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma
por: Ren, Xiaojing, et al.
Publicado: (2018)

Relevant mediators involved in and therapies targeting the inflammatory response induced by activation of the NLRP3 inflammasome in ischemic stroke
por: Xu, Qingxue, et al.
Publicado: (2021)

CSRP1 Promotes Colon Adenocarcinoma Growth and Serves as an Independent Risk Biomarker for Worse Prognosis
por: Yu, Senlong, et al.
Publicado: (2023)

Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma
por: Cai, Zhixiong, et al.
Publicado: (2014)

Aldehyde dehydrogenase serves as a biomarker for worse survival profiles in ovarian cancer patients: an updated meta-analysis
por: Xia, Yan, et al.
Publicado: (2018)

Biological function analysis of ARHGAP39 as an independent prognostic biomarker in hepatocellular carcinoma
por: Ding, Yongqi, et al.
Publicado: (2023)

DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway
por: Zhang, Tong, et al.
Publicado: (2018)

Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation
por: Zhang, Donghong, et al.
Publicado: (2016)

PROZ May Serve as a Prognostic Biomarker for Early Hepatocellular Carcinoma
por: Jiang, Xiaocong, et al.
Publicado: (2021)

Downregulation of CYP2E1 is associated with poor prognosis and tumor progression of gliomas
por: Ye, Liguo, et al.
Publicado: (2021)

Does hereditary angioedema make COVID-19 worse?
por: Xu, Yingyang, et al.
Publicado: (2020)

GLUT10 is a novel immune regulator involved in lung cancer immune cell infiltration and predicts worse survival when transcriptionally downregulated
por: Jian, Lijuan, et al.
Publicado: (2023)

HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer
por: Wang, Feng-Jiao, et al.
Publicado: (2021)

Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data
por: Zeng, Zhili, et al.
Publicado: (2021)

OPN and αvβ3 Expression are Predictors of Disease Severity and Worse Prognosis in Hepatocellular Carcinoma
por: Jin, Yi, et al.
Publicado: (2014)

NEK2 serves as a prognostic biomarker for hepatocellular carcinoma
por: Li, Gang, et al.
Publicado: (2017)

Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods
por: Xie, Qingqing, et al.
Publicado: (2022)

Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma
por: Zhang, Zhiguo, et al.
Publicado: (2015)

Ferroptosis and endoplasmic reticulum stress in ischemic stroke
por: Li, Yina, et al.
Publicado: (2023)

Downregulation of serum survivin correlates with increased inflammation, enhanced disease severity and worse prognosis in sepsis patients
por: Zhang, Yanmin, et al.
Publicado: (2020)

The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer
por: Cai, Yuan, et al.
Publicado: (2022)

Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer
por: Zhao, Zitong, et al.
Publicado: (2019)

What are the Risk Factors for Worse Outcomes of Meniscus Surgery in 23-39-Year-Old Patients Ligamentously Stable Knees?
por: Flynn, Megan, et al.
Publicado: (2020)

STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway
por: Zhang, Chengfei, et al.
Publicado: (2021)

Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Response to Letter]
por: Yang, Xin, et al.
Publicado: (2021)

Decrease of 5-Hydroxymethylcytosine Is Associated with Progression of Hepatocellular Carcinoma through Downregulation of TET1
por: Liu, Chungang, et al.
Publicado: (2013)

Guanylate‐binding protein 1 correlates with advanced tumor features, and serves as a prognostic biomarker for worse survival in lung adenocarcinoma patients
por: Wan, Quanchao, et al.
Publicado: (2020)

LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
por: Lovat, Francesca, et al.
Publicado: (2013)

EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis
por: Gu, Fangming, et al.
Publicado: (2019)

Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
por: Maeda, Takahiro, et al.
Publicado: (2019)

TMEM147 Correlates with Immune Infiltration and Serve as a Potential Prognostic Biomarker in Hepatocellular Carcinoma
por: Cheng, Sheng, et al.
Publicado: (2023)

Hypermethylation Leads to Bone Morphogenetic Protein 6 Downregulation in Hepatocellular Carcinoma
por: He, Yinghua, et al.
Publicado: (2014)

Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum
por: Zhao, Zitong, et al.
Publicado: (2023)

Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2020)

CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma
por: Zhou, Huifang, et al.
Publicado: (2019)

SAMD13 serves as a useful prognostic biomarker for hepatocellular carcinoma
por: Yoo, Wonbeak, et al.
Publicado: (2023)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2017)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma
por: Su, Qiuming, et al.
Publicado: (2022)

Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells
por: Xing, Zhiyuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h4bfptthp021ita84trcjgomqr